BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bixquert M. Maintenance therapy in gastro-oesophageal reflux disease. Drugs. 2005;65 Suppl 1:59-66. [PMID: 16335859 DOI: 10.1111/j.1365-2036.2007.03381.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Cho JH, Koo JY, Kim KO, Lee SH, Jang BI, Kim TN. On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study. Medicine (Baltimore) 2018;97:e12732. [PMID: 30412065 DOI: 10.1097/MD.0000000000012732] [Reference Citation Analysis]
2 Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-28; quiz 329. [PMID: 23419381 DOI: 10.1038/ajg.2012.444] [Cited by in Crossref: 940] [Cited by in F6Publishing: 680] [Article Influence: 104.4] [Reference Citation Analysis]
3 Metaxas ES, Bain KT. Review of Proton Pump Inhibitor Overuse in the US Veteran Population. Journal of Pharmacy Technology 2015;31:167-76. [DOI: 10.1177/8755122515575177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
5 Smith CD. Surgical therapy for gastroesophageal reflux disease: indications, evaluation, and procedures. Gastrointest Endosc Clin N Am. 2009;19:35-48, v-vi. [PMID: 19232279 DOI: 10.1016/j.giec.2008.12.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
6 Tang RS, Wu JC. Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole. Clin Interv Aging 2013;8:1433-43. [PMID: 24187492 DOI: 10.2147/CIA.S41350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
7 Bayerdörffer E, Bigard MA, Weiss W, Mearin F, Rodrigo L, Dominguez Muñoz JE, Grundling H, Persson T, Svedberg LE, Keeling N. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016;16:48. [PMID: 27080034 DOI: 10.1186/s12876-016-0448-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
8 Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2012;10:338-345; quiz e39-40. [PMID: 22178462 DOI: 10.1016/j.cgh.2011.12.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
9 Zhang LY, Lan Y, Wang Q. Etiological differences for different types of gastroesophageal reflux disease. Shijie Huaren Xiaohua Zazhi 2009; 17(8): 829-833 [DOI: 10.11569/wcjd.v17.i8.829] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans ME. Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error. Digestion 2013;87:85-90. [PMID: 23364219 DOI: 10.1159/000345144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 de Bortoli N, Tolone S, Frazzoni M, Martinucci I, Sgherri G, Albano E, Ceccarelli L, Stasi C, Bellini M, Savarino V, Savarino EV, Marchi S. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol 2018;31:639-48. [PMID: 30386113 DOI: 10.20524/aog.2018.0314] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
12 Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392-1413, 1413.e1-1413.e5. [PMID: 18801365 DOI: 10.1053/j.gastro.2008.08.044] [Cited by in Crossref: 264] [Cited by in F6Publishing: 203] [Article Influence: 18.9] [Reference Citation Analysis]
13 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
14 Zhang J, Xu YQ, Yang ZX. Comparison of clinical characteristics among Barrett's esophagus, erosive esophagitis and non-erosive reflux disease. Shijie Huaren Xiaohua Zazhi 2009; 17(31): 3249-3254 [DOI: 10.11569/wcjd.v17.i31.3249] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009;5:1113-1124. [PMID: 19606942 DOI: 10.1517/17425250903124363] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
16 Wang C, Hunt RH. Medical management of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2008;37:879-899, ix. [PMID: 19028323 DOI: 10.1016/j.gtc.2008.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
17 Xirouchakis E, Kamberoglou D, Kalos D, Zambeli E, Doulgeroglou V, Tzias V. The Effect of Gastroesophageal Flap Valve Appearance on the Management of Patients with Symptoms of Gastroesophageal Reflux Disease. Dig Dis Sci 2009;54:328-32. [DOI: 10.1007/s10620-008-0347-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
18 Kamada T, Fujimura Y, Gotoh K, Imamura H, Manabe N, Kusunoki H, Inoue K, Shiotani A, Hata J, Haruma K. A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori-Negative Primary Care Patients with Dyspepsia in Japan. Gut Liver 2013;7:16-22. [PMID: 23423422 DOI: 10.5009/gnl.2013.7.1.16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Nagahara A, Hojo M, Asaoka D, Watanabe S. Maintenance therapy of gastroesophageal reflux disease. Clin J Gastroenterol 2010;3:61-8. [PMID: 26189996 DOI: 10.1007/s12328-010-0139-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Andréasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med. 2011;270:50-57. [PMID: 21205026 DOI: 10.1111/j.1365-2796.2010.02340.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
21 Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022:S0016-5085(21)04083-X. [PMID: 35183361 DOI: 10.1053/j.gastro.2021.12.247] [Reference Citation Analysis]
22 Huerta-Iga FM, Tamayo-de la Cuesta JL, Noble-Lugo A, Remes-Troche JM, Valdovinos-Díaz MA, Carmona-Sánchez RI; el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico 2011. [The Mexican consensus on gastroesophageal reflux disease. Part I]. Rev Gastroenterol Mex 2012;77:193-213. [PMID: 23153413 DOI: 10.1016/j.rgmx.2012.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Huerta-iga F, Bielsa-fernández M, Remes-troche J, Valdovinos-díaz M, Tamayo-de la Cuesta J. Diagnosis and treatment of gastroesophageal reflux disease: recommendations of the Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México (English Edition) 2016;81:208-22. [DOI: 10.1016/j.rgmxen.2016.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Xiao J, Yang Y, Zhu Y, Qin Y, Li Y, Fu M, Zhai Z, Zhu L. Efficacy and Safety of Traditional Chinese Medicine on Nonerosive Reflux Disease: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2018;2018:1505394. [PMID: 29977310 DOI: 10.1155/2018/1505394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Smith CD. Antireflux Surgery. Surgical Clinics of North America 2008;88:943-58. [DOI: 10.1016/j.suc.2008.06.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Bi D, Katzka DA, Lavey CJ, Geno DM, Ravi K. Erosive Esophagitis Portends a Benign Clinical Course in the Majority of Patients. Dig Dis Sci 2020;65:3244-52. [PMID: 31907769 DOI: 10.1007/s10620-019-06027-1] [Reference Citation Analysis]
27 Scarpignato C, Tolone S. Addressing long-term PPI safety. Digestive and Liver Disease 2020;52:853-6. [DOI: 10.1016/j.dld.2020.05.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Mckeage K, Blick SKA, Croxtall JD, Lyseng-williamson KA, Keating GM. Esomeprazole: A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults. Drugs 2008;68:1571-607. [DOI: 10.2165/00003495-200868110-00009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
29 Kushner PR, Peura DA. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect? Adv Ther 2011;28:367-88. [PMID: 21484335 DOI: 10.1007/s12325-011-0013-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
30 Walker D, Ng Kwet Shing R, Jones D, Gruss HJ, Reguła J. Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec. PLoS One 2015;10:e0116308. [PMID: 25706883 DOI: 10.1371/journal.pone.0116308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
31 Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the Use of Proton Pump Inhibitors in Adult Patients: . Drugs 2008;68:925-47. [DOI: 10.2165/00003495-200868070-00004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
32 Jung HK, Hong SJ, Jo YJ, Jeon SW, Cho YK, Lee KJ, Lee JS, Park HJ, Shin ES, Lee SH. [Updated guidelines 2012 for gastroesophageal reflux disease]. Korean J Gastroenterol. 2012;60:195-218. [PMID: 23089906 DOI: 10.4166/kjg.2012.60.4.195] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
33 Huerta-Iga F, Bielsa-Fernández MV, Remes-Troche JM, Valdovinos-Díaz MA, Tamayo-de la Cuesta JL; en representación del Grupo para el estudio de la ERGE 2015. Diagnosis and treatment of gastroesophageal reflux disease: recommendations of the Asociación Mexicana de Gastroenterología. Rev Gastroenterol Mex 2016;81:208-22. [PMID: 27595382 DOI: 10.1016/j.rgmx.2016.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Laine L, Nagar A. Long-Term PPI Use: Balancing Potential Harms and Documented Benefits. Am J Gastroenterol 2016;111:913-5. [PMID: 27113114 DOI: 10.1038/ajg.2016.156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
35 Farup PG, Heibert M, Høeg V. Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial. BMC Complement Altern Med 2009;9:3. [PMID: 19236727 DOI: 10.1186/1472-6882-9-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Dent J, Kahrilas PJ, Vakil N, Van Zanten SV, Bytzer P, Delaney B, Haruma K, Hatlebakk J, McColl E, Moayyedi P, Stanghellini V, Tack J, Vaezi M. Clinical trial design in adult reflux disease: a methodological workshop. Aliment Pharmacol Ther 2008;28:107-26. [PMID: 18384662 DOI: 10.1111/j.1365-2036.2008.03700.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
37 Smeets HM, Hoes AW, Zuithoff NP, van Dijk PC, van der Lee AP, de Wit NJ. A health insurance company-initiated practice support intervention for optimizing acid-suppressing drug prescriptions in primary care: . European Journal of Gastroenterology & Hepatology 2011;23:664-70. [DOI: 10.1097/meg.0b013e328347d503] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG, North American Society for Pediatric Gastroenterology Hepatology and Nutrition, European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498-547. [PMID: 19745761 DOI: 10.1097/mpg.0b013e3181b7f563] [Cited by in Crossref: 357] [Cited by in F6Publishing: 178] [Article Influence: 29.8] [Reference Citation Analysis]
39 van Zanten SJ, Henderson C, Hughes N. Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review. Can J Gastroenterol 2012;26:196-204. [PMID: 22506259 DOI: 10.1155/2012/235476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
40 Simonson W. Implications of over-the-counter proton pump inhibitors for patient counseling by pharmacists. Am J Ther 2013;20:676-84. [PMID: 21642828 DOI: 10.1097/MJT.0b013e318217a5d1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Tonini M, Vigneri S, Neri M, Cuomo R, Savarino V, Pace F. Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors. Digestion 2008;76:171-8. [DOI: 10.1159/000111985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
43 Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2021. [PMID: 34807007 DOI: 10.14309/ajg.0000000000001538] [Reference Citation Analysis]
44 Pace F, Porro GB. On-demand PPI therapy in GERD. Curr Treat Options Gastroenterol 2008;11:35-42. [PMID: 21063862 DOI: 10.1007/s11938-008-0005-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
45 Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, Iijima K, Koike T, Omura N, Nomura T, Kawamura O, Ohara S, Ozawa S, Kinoshita Y, Mochida S, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. [DOI: 10.1007/s00535-022-01861-z] [Reference Citation Analysis]
46 Liakakos T, Karamanolis G, Patapis P, Misiakos EP. Gastroesophageal reflux disease: medical or surgical treatment? Gastroenterol Res Pract. 2009;2009:371580. [PMID: 20069112 DOI: 10.1155/2009/371580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
47 Umezawa M, Kawami N, Hoshino S, Hoshikawa Y, Koizumi E, Takenouchi N, Hanada Y, Kaise M, Iwakiri K. Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis. Digestion 2018;97:309-15. [PMID: 29514137 DOI: 10.1159/000485795] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
48 Omura N, Kashiwagi H, Yano F, Tsuboi K, Yanaga K. Postoperative recurrence factors of GERD in the elderly after laparoscopic fundoplication. Esophagus 2010;7:31-5. [DOI: 10.1007/s10388-009-0220-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 AlMutairi H, O'Dwyer M, McCarron M, McCallion P, Henman MC. The use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational study. Saudi Pharm J 2018;26:1012-21. [PMID: 30416357 DOI: 10.1016/j.jsps.2018.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, Ghoshal UC, Ahuja V, Rao GV, Devadas K, Dutta AK, Jain A, Kedia S, Dama R, Kalapala R, Alvares JF, Dadhich S, Dixit VK, Goenka MK, Goswami BD, Issar SK, Leelakrishnan V, Mallath MK, Mathew P, Mathew P, Nandwani S, Pai CG, Peter L, Prasad AVS, Singh D, Sodhi JS, Sud R, Venkataraman J, Midha V, Bapaye A, Dutta U, Jain AK, Kochhar R, Puri AS, Singh SP, Shimpi L, Sood A, Wadhwa RT. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol 2019;38:411-40. [PMID: 31802441 DOI: 10.1007/s12664-019-00979-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
51 Farrell C, Morgan M, Tully O, Wolov K, Kearney K, Ngo B, Mercogliano G, Thornton JJ, Valenzano MC, Mullin JM. Transepithelial leak in Barrett's esophagus patients: The role of proton pump inhibitors. World J Gastroenterol 2012; 18(22): 2793-2797 [PMID: 22719187 DOI: 10.3748/wjg.v18.i22.2793] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
52 Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 2018; 24(14): 1550-1561 [PMID: 29662293 DOI: 10.3748/wjg.v24.i14.1550] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
53 Falkenback D, Öberg S, Johnsson F, Johansson J. Is the course of gastroesophageal reflux disease progressive? A 21-year follow-up. Scandinavian Journal of Gastroenterology 2009;44:1277-87. [DOI: 10.3109/00365520903314157] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
54 Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, Dronova OB, Kucheryavyy YA, Pirogov SS, Sayfutdinov RG, Uspenskiy YP, Sheptulin AA, Andreev DN, Rumyantseva DE. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:70-97. [DOI: 10.22416/1382-4376-2020-30-4-70-97] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 8.5] [Reference Citation Analysis]
55 Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152:706-715. [PMID: 28257716 DOI: 10.1053/j.gastro.2017.01.031] [Cited by in Crossref: 322] [Cited by in F6Publishing: 270] [Article Influence: 64.4] [Reference Citation Analysis]
56 Liu F, Yao P. Relationship between primary bile reflux gastritis and gastroesophageal reflux disease. Shijie Huaren Xiaohua Zazhi 2012; 20(8): 685-689 [DOI: 10.11569/wcjd.v20.i8.685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Kim J, Blackett JW, Jodorkovsky D. Strategies for Effective Discontinuation of Proton Pump Inhibitors. Curr Gastroenterol Rep 2018;20:27. [PMID: 29767318 DOI: 10.1007/s11894-018-0632-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
58 Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38:190-201. [PMID: 23718547 DOI: 10.1111/apt.12349] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
59 Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11:27-37. [PMID: 27840364 DOI: 10.5009/gnl15502] [Cited by in Crossref: 147] [Cited by in F6Publishing: 119] [Article Influence: 29.4] [Reference Citation Analysis]
60 Domingues G, Moraes-Filho JPP. GASTROESOPHAGEAL REFLUX DISEASE: A PRACTICAL APPROACH. Arq Gastroenterol 2021;58:525-33. [PMID: 34909861 DOI: 10.1590/S0004-2803.202100000-94] [Reference Citation Analysis]
61 Jung SB, Nagaraja V, Kapur A, Eslick GD. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis: Vitamin B12 deficiency. Intern Med J 2015;45:409-16. [DOI: 10.1111/imj.12697] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
62 Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, Huang P, Ajani J, Hung MC. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res 2008;68:2632-40. [PMID: 18413730 DOI: 10.1158/0008-5472.CAN-07-5460] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
63 Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24:905-921. [PMID: 21126703 DOI: 10.1016/j.bpg.2010.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
64 Khan Z, Alastal Y, Khan MA, Khan MS, Khalil B, Shrestha S, Kamal F, Nawras A, Howden CW. On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2018;2018:6417526. [PMID: 30158966 DOI: 10.1155/2018/6417526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Lee ES, Kim N, Lee SH, Park YS, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009;30:154-164. [PMID: 19392871 DOI: 10.1111/j.1365-2036.2009.04021.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
66 Ono S, Kato M, Ono Y, Imai A, Yoshida T, Shimizu Y, Asaka M. Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules. J Gastroenterol Hepatol. 2009;24:639-645. [PMID: 19032447 DOI: 10.1111/j.1440-1746.2008.05644.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
67 Xiao YL, Nie YQ, Hou XH, Xie PY, Fang JY, Yuan YZ, Zhou LY, Zhao NQ, Chen MH. The efficacy, safety and cost-effectiveness of hydrotalcite versus esomeprazole in on-demand therapy of NERD: A multicenter, randomized, open-label study in China. J Dig Dis. 2013;14:463-468. [PMID: 23659834 DOI: 10.1111/1751-2980.12069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]